HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Impaired innate immune alveolar macrophage response and the predilection for COPD exacerbations.

AbstractBACKGROUND:
Alveolar macrophages (AM) in COPD have fundamentally impaired responsiveness to Toll-like receptor 2 (TLR2) and TLR4 ligands of non-typeable Haemophilus influenzae (NTHI). However, the contribution of innate immune dysfunction to exacerbations of COPD is unexplored. We hypothesised that impaired innate AM responses in COPD extend beyond NTHI to other pathogens and are linked with COPD exacerbations and severity.
METHODS:
AMs, obtained by bronchoalveolar lavage from 88 volunteers with stable-to-moderate COPD, were incubated with respiratory pathogens (NTHI, Moraxella catarrhalis (MC), Streptococcus pneumoniae (SP) and TLR ligands lipopolysaccharide, Pam3Cys) and elicited IL-8 and TNF-α were measured by microsphere flow cytometry. NF-κB nuclear translocation was measured by colorimetric assay. AM TLR2 and TLR4 expression was determined by immunolabeling and quantitation of mean fluorescent indices. Participants were monitored prospectively for occurrence of COPD exacerbations for 1 year following bronchoscopy. Non-parametric analyses were used to compare exacerbation-prone and non-exacerbation-prone individuals.
RESULTS:
29 subjects had at least one exacerbation in the follow-up period (exacerbation-prone) and 59 remained exacerbation-free (non-exacerbation-prone). AMs of exacerbation-prone COPD donors were more refractory to cytokine induction by NTHI (p=0.02), MC (p=0.045) and SP (p=0.046), and to TLR2 (p=0.07) and TLR4 (p=0.028) ligands, and had diminished NF-κB nuclear activation, compared with non-exacerbation-prone counterparts. AMs of exacerbation-prone subjects were more refractory to TLR2 upregulation by MC and SP (p=0.04 each).
CONCLUSIONS:
Our results support a paradigm of impaired innate responses of COPD AMs to respiratory pathogens, mediated by impaired TLR responses, underlying a propensity for exacerbations in COPD.
AuthorsCharles S Berenson, Ragina L Kruzel, Ellana Eberhardt, Ree Dolnick, Hans Minderman, Paul K Wallace, Sanjay Sethi
JournalThorax (Thorax) Vol. 69 Issue 9 Pg. 811-8 (Sep 2014) ISSN: 1468-3296 [Electronic] England
PMID24686454 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, U.S. Gov't, Non-P.H.S.)
CopyrightPublished by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
Chemical References
  • Interleukin-8
  • Ligands
  • Lipopolysaccharides
  • Lipoproteins
  • NF-kappa B
  • TLR2 protein, human
  • TLR4 protein, human
  • Toll-Like Receptor 2
  • Toll-Like Receptor 4
  • Tumor Necrosis Factor-alpha
  • N-palmitoyl-S-(2,3-bis(palmitoyloxy)propyl)cysteinyl-seryl-lysyl-lysyl-lysyl-lysine
Topics
  • Cells, Cultured
  • Coculture Techniques
  • Disease Progression
  • Female
  • Haemophilus influenzae (immunology)
  • Humans
  • Immunity, Innate
  • Interleukin-8 (immunology, metabolism)
  • Ligands
  • Lipopolysaccharides
  • Lipoproteins (pharmacology)
  • Macrophages, Alveolar (immunology, metabolism, microbiology)
  • Male
  • Middle Aged
  • Moraxella catarrhalis (immunology)
  • NF-kappa B (metabolism)
  • Pulmonary Disease, Chronic Obstructive (immunology, microbiology, physiopathology)
  • Severity of Illness Index
  • Signal Transduction (drug effects)
  • Streptococcus pneumoniae (immunology)
  • Toll-Like Receptor 2 (immunology, metabolism)
  • Toll-Like Receptor 4 (immunology, metabolism)
  • Tumor Necrosis Factor-alpha (immunology, metabolism)
  • Up-Regulation

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: